^
Association details:
| Biomarker: | MCL1 underexpression |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | bortezomib (Proteasome inhibitor) + A-1331852 (Bcl-xL inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models
Excerpt:
BCL-2 is expressed but sensitivity to venetoclax correlated with high BCL-2 and low BCL-XL or MCL-1 expression...xenografts that expressed BCL-XL, MCL-1, and BCL-2 were more sensitive to the combination of bortezomib with a BCL-XL selective inhibitor (A-1331852)…
DOI:
10.1158/1535-7163.MCT-15-0730
